To the European Patent Office
`
`Entry into the European phase (EPO as designated or elected
`Office)
`
`European application number
`PCT application number
`PCT publication number
`Applicant’s or representative’s reference
`1. Applicant
`Particulars of the applicant(s) are contained in the international publication or were
`recorded by the International Bureau subsequent to the international publication.
`
`EP03753571.3
`PCT/EP2003/50176
`WO03106461
`TIP 033 EPO/PCT
`
`Changes which have not yet been recorded by the International Bureau are set out here: []
`
`Address for correspondence
`
`2. Representative 1
`This is the representative who will be listed in the Ragister of European Patents and to
`whom notifications will be made
`Name
`
`Address of place of business
`
`Telephone
`
`Fax
`
`e-mall
`
`Any additional representative(s) is/are listed here:
`
`3. Authorisation
`An individual authorisation is attached.
`
`A general authorisation has been registered under No:
`
`A general authorisation has been filed, but not yet registered.
`
`The authorisation filed with the EPO as PCT receiving Office expressly includes the
`European phase.
`
`4. Request for examination
`Examination of the application under Art. 94 EPC is hereby requested. The examination
`fee is being (has been, will be) paid.
`
`Request for examination in an admissible non-EPO language:
`
`DAELEMANS, Frank
`
`Tibotec-Virco Comm. VA
`Generaal De Witt~laan L 11B 3
`B-2800 Mechelen
`Belgium
`
`+32 15 401 270
`
`+32 15 275 478
`
`~aelema@tibbe.jnj.com
`
`[]
`
`44036
`
`larrtar leis seo scredO an iarratais de bhun
`Airteaga194.
`
`Lupin Ex. 1019 (Page 1 of 5)
`
`

`

`5. Copies
`One or more additional sets of copies of the documents cited in the supplementary
`European search report are hereby requested.
`
`Number of additional sets of copies
`
`6. Documents intended for proceedings before the EPO
`6.1 Proceedings before the EPO as designated Office (PCT I) are to be based on the
`following documents:
`the application documents published by the International Bureau (with all claims,
`description and drawings), where applicable with amended claims under Art. 19 PCT
`
`unless replaced by the amendments attached.
`
`Where necessary, clarifications should be attached as ’Other Documents’
`
`6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following
`docu ments:
`the documents on which the international preliminary examination report is based,
`including any annexes
`
`unless replaced by the amendments attached.
`
`Where necessary, clarifications should be attached as ’Other Documents’
`
`If the EPO as International Preliminary Examining Authority has been supplied with test
`reports, these may be used as the basis of proceedings before the EPO.
`
`[]
`
`7. Translations
`Translations in one of the official languages of the EPO (English, French, German) ere
`attached as crossed below:
`
`* In proceedings before the EPO as designated or elected Office (PCT I + II):
`
`Translation of the international application (description, claims, any text in the
`drawings) as originally filed, of the abstract as published and of any indication under
`Rule 13his.3 and 13his.4 PCT regarding biological matedal
`
`Translation of priority application(s)
`
`It is hereby declared that the intemational application as originally filed is a complete
`translation of the previous application (Rule 38(5) EPC)
`
`* In addition, in proceedings before the EPO as designated Office (PCT I):
`
`[]
`
`[]
`
`Translation of amended claims and any statement under Art. 19 PCT, if the claims as []
`amended are to form the basis for the proceedings before the EPO (see Section 6).
`
`* In addition, in proceedings before the EPO as elected office (PCT I1):
`
`Translation of annexes to the international preliminary examination report
`
`Lupin Ex. 1019 (Page 2 of 5)
`
`

`

`8. Biological material
`The invention relates to and/or uses biological material deposited under Rule 28 EPC.
`
`The particulars referred to in Rule 28(1)(c) EPC (if not yet known, the depository
`institution and the identification reference(s) [number, symbols, etc.] of the depositor) are
`given in the international publication or in the translation submitted under Section 7 on:
`
`page(s) / line(s)
`
`A copy of the receipt(s) of deposit issued by the depositary institution
`
`is attached
`
`will be filed at a later date
`
`[]
`
`[]
`
`A waiver of the right to an undertaking from the requester pursuant to Rule 28(3) EPC is []
`attached.
`
`9. Nucleotide and amino acid sequences
`
`The items required under Rules 5.2 and 13ter PCT and Rule 111(3) EPC have already
`been furnished to the EPO.
`
`[]
`
`The sequence listing as part of the description is attached in PDF format.
`
`The sequence listing does not include matter that goes beyond the content of the
`application as filed.
`
`[]
`
`In addition, the sequence listing data is attached in computer-readable form in accordance []
`with WIPO Standard 25.
`
`The sequence listing data in computer-readable form in accordance with WIPO
`Standard 25 is identical to the sequence listing in PDF format.
`
`[]
`
`10. Designation fees
`
`10.1 It is currently intended to pay seven times the amount of the designation fee. The
`designation fees for all the EPC contracting states designated in the international
`application are thereby deemed to have been paid (Art. 2 No. 3 RFees).
`
`AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
`SI SK TR
`
`10.2 The declaration in No. 10.1 does not apply. Instead, it is currently intended to pay
`fewer than seven designation fees for the following EPC contracting states designated in
`the international application:
`
`It is requested that no communications under Rule 108(3) EPC be issued in respect of
`any contracting states not indicated.
`
`10.3 If an automatic debit order has been issued (Section 12), the EPO is authorised, on
`expiry of the basic period under Rule 107(1)(d) EPC, to debit seven times the amount of
`the designation fee. If states are indicated in No. 10.2, the EPO will debit designation fees
`for those states only, unless instructed otherwise before the basic period expires.
`
`Lupin Ex. 1019 (Page 3 of 5)
`
`

`

`11. Extension of the European patent
`
`This application is also considered as being a request for extension to all the
`non-contracting states to the EPC designated in the international application with which
`"extension agreements" were in force on the date of filing the international application.
`However, the extension only takes effect if the prescribed extension fee is paid.
`
`It is currently intended to pay the extension fee for the following states:
`
`AL LV MK
`
`12. Automatic debit order
`
`Currency
`
`EUR
`
`The EPO is hereby authorised, under the Arrangements for the automatic debiting
`procedure, to debit from the deposit account below any fees and costs falling due. For
`designation fees, see "States".The EPO is also authorised, on expiry of the basic period
`for paying the extension fees, to debit those fees for each of the "extension states"
`indicated in "States", unless instructed otherwise before the said period expires.
`
`Deposit account number
`Account holder
`
`28020069
`Tibotec Pharmaceuticals Ltd.
`
`13. Reimbursements (if any) should be made to the following EPO
`deposit account:
`
`[]
`
`Number and account holder
`
`28020069, Tibotec Pharmaceuticals Ltd.
`
`14. Fees
`
`14-1
`14-2
`14-3
`14-4
`14-5
`
`14-6
`14-7
`14-8
`14-9
`
`002 Search fee
`005 Designation fee
`006 Examination fee
`015 Claims fee
`020 Basic national fee for an international
`application
`402 Extension fee LT
`403 Extension fee LV
`404 Extension fee AL
`406 Extension fee MK
`
`Total:
`
`15. Annotations
`15-1. Note (for EPO) (EP Phase)
`
`Factor applied
`
`0
`7
`1 (80%)
`4
`1
`
`1
`1
`1
`1
`
`Fee schedule
`690.00
`75.00
`1 430.00
`40.00
`90.00
`
`Amount~ be paid
`0.00
`525,00
`1 144,00
`160,00
`90.00
`
`102.00
`102.00
`102.00
`102.00
`EUR
`
`102.00
`102.00
`102.00
`102.00
`2 327.00
`
`Extension state Lithuania (Frank
`Daelemans; 01/12/2004)
`Pursuant to the notice from the EPO
`regarding the accession of Lithuania (LT) to
`the EPC, applicant wishes to designate LT
`as extension state for the present european
`patent application
`
`Lupin Ex. 1019 (Page 4 of 5)
`
`

`

`15-2. Note (for EPO) (EP Phase)
`
`Limited possibilities of current epoline
`software (Frank Daelemans; 01/12/2004)
`The current epoline software does not
`foresee a checkbox to designate Lithuania
`as extension state
`
`16. Signature(s) of applicant(s) or representative
`
`Place:
`Date:
`Signed by:
`
`Capacity:
`
`Mechelen
`3 December 2004
`Subject: BE, Tibotec-Virco Comm. VA, F. Daelemans 1037
`Issuer:, European Patent Office, European Patent Office CA
`( Representative )
`
`For employees (Art. 133(3) EPC) having a general authorisation:
`
`General authorisation No.
`
`Lupin Ex. 1019 (Page 5 of 5)
`
`